Absolute numbers of NK cells at D+28 after dUCBT are associated with clinical outcomes. (A) 2-year DFS of low, medium, and high NK groups (28%, 46%, and 55%; *shows comparison of low NK vs high NK groups where P = .04). (B) 2-year NRM of low, medium, and high NK groups (41%, 26%, and 18%; P = .08). (C) 2-year relapse incidence in the low, medium, and high NK groups (30%, 28%, and 27%; P = .94). (D) 100-day grade II-IV acute GVHD in the low, medium, and high NK patients (49%, 46%, and 47%; P = .51).